WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Mark Saad Biography and Net Worth

Director of Axsome Therapeutics

Mr. Saad has been a member of our board of directors since December 2014.

Mr. Saad is currently a Partner and Chief Operating Officer of Alethea Capital Management, LLC, an asset management firm based in San Diego. Between August 2014 and February 2017 he served as the Chief Financial Officer of Bird Rock Bio, Inc., a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Previously, he served as Chief Financial Officer of Cytori Therapeutics from 2004 to 2014, where he was responsible for finance and accounting, business development, and other operating functions. Prior to Cytori, he served as Executive Director of UBS Investment Bank, where he was the Chief Operating Officer of the Global Healthcare Group. Prior to UBS, Mr. Saad was part of the Health Care Investment Banking Group at Salomon Smith Barney. Mr. Saad holds a Bachelor of Arts from Villanova University.

What is Mark E. Saad's net worth?: The estimated net worth of Mark E. Saad is at least $907,481.46 as of September 11th, 2024. Mr. Saad owns 10,002 shares of Axsome Therapeutics stock worth more than $907,481 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Saad may own. Learn More about Mark E. Saad's net worth.
How do I contact Mark E. Saad?: The corporate mailing address for Mr. Saad and other Axsome Therapeutics executives is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. Axsome Therapeutics can also be reached via phone at (212) 332-3241. Learn More on Mark E. Saad's contact information.
Has Mark E. Saad been buying or selling shares of Axsome Therapeutics?: Mark E. Saad has not been actively trading shares of Axsome Therapeutics during the last quarter. Most recently, Mark E. Saad sold 11,016 shares of the business's stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a transaction totalling $1,005,870.96. Following the completion of the sale, the director now directly owns 10,002 shares of the company's stock, valued at $913,282.62. Learn More on Mark E. Saad's trading history.
Who are Axsome Therapeutics' active insiders?: Axsome Therapeutics' insider roster includes Mark Coleman (Director), Mark Jacobson (COO), Roger Jeffs (Director), Nick Pizzie (CFO), and Mark Saad (Director). Learn More on Axsome Therapeutics' active insiders.
Are insiders buying or selling shares of Axsome Therapeutics?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 126,552 shares worth more than $10,005,148.57. The most recent insider tranaction occured on September, 11th when Director Mark E Saad sold 11,016 shares worth more than $1,005,870.96. Insiders at Axsome Therapeutics own 22.4% of the company. Learn More about insider trades at Axsome Therapeutics.
Information on this page was last updated on 9/11/2024.

Mark E. Saad Insider Trading History at Axsome Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/11/2024	Sell	11,016	$91.31	$1,005,870.96	10,002
11/17/2021	Buy	3,000	$34.53	$103,590.00
5/23/2019	Buy	3,500	$22.33	$78,155.00	7,002

Mark E. Saad Buying and Selling Activity at Axsome Therapeutics

Axsome Therapeutics Company Overview

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Today's Range

Now: $90.73

$87.69

$93.12

50 Day Range

MA: $93.65

$85.42

$100.49

2 Week Range

Now: $90.73

$64.11

$105.00

Volume

956,380 shs

Average Volume

610,942 shs

Market Capitalization

$4.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18